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Simple Summary: Tumours consist of multiple groups of similar cells resulting from differing evolu-
tionary trajectories, i.e., subclones. These subclones are prevalent in clear cell renal cell carcinoma
(ccRCC). The aim of this study is to determine how similar or dissimilar the subclones in 89 ccRCC
tumours are from one another regarding their gene mutations and expression profiles, i.e., the extent
of intra-tumour heterogeneity. The implications of these alterations with respect to signalling path-
ways is also assessed. Deep sequencing allows for the identification of mutations with low-allele
frequencies, providing a more comprehensive view of the heterogeneity present in the tumours. With
an average of 62% of mutations having been identified in only one of the two biopsies, some of which
in turn are found to impact gene expression, the complex makeup of ccRCC tumours is evident, and
this can drastically influence treatment outcome.
Abstract: Intra-tumour heterogeneity is the molecular hallmark of renal cancer, and the molecular
tumour composition determines the treatment outcome of renal cancer patients. In renal cancer
tumourigenesis, in general, different tumour clones evolve over time. We analysed intra-tumour
heterogeneity and subclonal mutation patterns in 178 tumour samples obtained from 89 clear cell renal
cell carcinoma patients. In an initial discovery phase, whole-exome and transcriptome sequencing
data from paired tumour biopsies from 16 ccRCC patients were used to design a gene panel for
follow-up analysis. In this second phase, 826 selected genes were targeted at deep coverage in an
extended cohort of 89 patients for a detailed analysis of tumour heterogeneity. On average, we found
22 mutations per patient. Pairwise comparison of the two biopsies from the same tumour revealed
that on average, 62% of the mutations in a patient were detected in one of the two samples. In addition
to commonly mutated genes (VHL, PBRM1, SETD2 and BAP1), frequent subclonal mutations with
low variant allele frequency (<10%) were observed in TP53 and in mucin coding genes MUC6,
MUC16, and MUC3A. Of the 89 ccRCC tumours, 87 (~98%) harboured private mutations, occurring
in only one of the paired tumour samples. Clonally exclusive pathway pairs were identified using
the WES data set from 16 ccRCC patients. Our findings imply that shared and private mutations
significantly contribute to the complexity of differential gene expression and pathway interaction
and might explain the clonal evolution of different molecular renal cancer subgroups. Multi-regional
sequencing is central for the identification of subclones within ccRCC.
Keywords: intra-tumour heterogeneity; private mutations; clonal exclusivity
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1. Introduction
Tumours consist of genetically and phenotypically distinct cancer cell populations
that evolve over time through a process that involves mutation and selection [1]. The
presence of intra-tumour heterogeneity is well founded in renal cell carcinoma (RCC) with
multiple subclones in both the primary tumour and paired metastasis [2–6]. Gerlinger et al.
assessed the heterogeneity within 10 renal carcinomas, applying multi-regional sequencing.
A large degree of intra-tumour heterogeneity with respect to both somatic mutations and
somatic copy number variations was observed in all 10 tumours, with 75% of driver events
found to be subclonal [4,7]. Martinez et al. further showed in eight RCC that the diversity
within tumours is in some cases as high as the diversity between patients [8]. Therefore,
the number of somatic mutations may be undervalued when taking a single biopsy from a
solid tumour with only a subset of clones being present in the metastasis. This work laid
the foundation for the TracerX consortiums analysis of 101 RCCs with 1206 multi-regional
samples. When assessing the metastasis of these tumours, it was found that the majority of
the diversity accumulated in the primary tumour. It is within these primary tumours where
metastasis-competent subclones undergo selection [9]. The identification of subclonal
mutations is clinically relevant following observations that even low-frequency clones can
carry markers of prognosis and drive the process of metastasis [4]. Independent of genetic
heterogeneity, Okegawa et al. suggested that intra-tumour heterogeneity also presents
itself in the form of metabolic differences between tumour cells, further demonstrating the
complexity present within renal cancer [10].
Current treatment strategies for RCC include antiangiogenic and immune therapies,
the latter being effective in only a subset of cases [11–13]. Very recently, Motzer et al.
performed integrative multi-omics analyses of 823 renal carcinomas from a randomised
phase III clinical trial (IMotion 151) and identified seven robust molecular subtypes [14].
These molecular subgroups were associated with differential clinical outcomes following a
combination of an anti-angiogenesis agent (AA; bevacizumab, anti-VEGF) and an immune
checkpoint inhibitor (ICI; atezolizumab or anti-PD-L1) versus a VEGF receptor tyrosine
kinase inhibitor (sunitinib).
Here, we investigate the subclonal mutation composition of clear cell renal cell car-
cinoma in two steps (Figure 1). In the initial discovery phase, we analysed two spatially
separated biopsies and a matched normal sample from each of 16 ccRCC patients to provide
an overview of the diversity and to inform the selection of genes for the second in-depth
follow-up analysis. In the second phase, we used the constructed gene panel to sequence
826 genes at high coverage in 178 paired tumour samples and 89 matched normal samples
from 89 ccRCC patients. We found frequent subclonal mutations in TP53 and in mucin
coding genes MUC6, MUC16, and MUC3A. Further, we tested for clonal exclusivity to
identify combinations of signalling pathways that co-exist in the same tumour but in
different tumour cell clones.
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Figure 1. Experimental design. The first phase includes 16 clear cell renal cell carcinoma (ccRCC) patients of which
two spatially separated biopsies from the primary tumour and a matched normal sample were collected. Whole-exome
sequencing and transcriptome sequencing was performed and the detected mutations informed the selection of genes for the
panel of the second phase. The second phase includes an extended cohort of patients and the selected genes were targeted
with higher coverage. From a total of 89 patients, we analysed two spatially separated tumour biopsies and a matched
normal sample per patient. Fourteen of the patients in this panel data set were also among the 16 from the first phase.
2. Results
The assessment of whole-exome and transcriptomic sequencing data from paired
tumour biopsies along with a matched normal biopsy from 16 ccRCC patients revealed an
average of 40% of mutations were private and 31% of genes were differentially expressed
in only a single biopsy. A gene panel was produced consisting of 826 genes and targeted
for sequencing at deep coverage in a larger cohort of 89 patients, each with paired tumour
biopsies and a matched normal biopsy. We found that the mutational frequencies of
the most commonly aberrated genes in ccRCC found in our cohort are comparable to
those expected given data from previous large cohort studies. With the identification
of low-frequency mutations following deep sequencing, the average number of private
mutations increased to 62%. After the assignment of mutations to clones using the tool
Cloe, enrichment and pathway-level clonal exclusivity analysis was applied to identify
clonally exclusive pathway pairs.
2.1. Genetic and Transcriptomic Diversity in 16 Ccrcc Patients
The coverage of the whole-exome sequencing (WES) data was on average 85x, and
mutation calling (see Methods) identified between 29 and 130 single-nucleotide variants
(SNVs), insertions, and deletions (indels) per patient (Figure 2A). The fraction of mutations
that was only detected in one of the two biopsies from the same tumour was on average
40%, which indicates high levels of intra-tumour genetic diversity. These mutations are
referred to as private, whereas mutations detected in both tumour samples of a patient are
known as shared.
From the RNA-sequencing (RNA-seq) data, the differentially expressed genes were
called by comparing each tumour sample to its paired normal using both single and paired-
end data (see Methods). We found an average of 6364 genes per patient to be upregulated
and 6598 genes downregulated (Figure 2B) with an average of 31% of differentially ex-
pressed genes being detected only in one of the two biopsies. Pathway overrepresentation
analysis was performed with the set of differentially expressed genes using the Reactome
pathway database [15]. Among the most overrepresented pathways are many pathways
related to translation, signal transduction and growth factors (Figure 2C). The signalling
pathways involving the growth factors PDGF, VEGF, SCF, or the growth factor receptor
EGFR are deregulated in many patients. Of note, the vascular endothelial growth factor
A (VEGFA), important for angiogenesis, cell growth, and survival [11] is upregulated in
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all patients of this data set. The most overrepresented pathways related to translation are
highly overrepresented in patients 4, 15, and 16. They are enriched only privately in one
tumour sample of patients 2, 3, 14 and 15 each, indicating that these deregulated processes
are subclonal in these tumours. Assessment of the similarity between samples as measured
by the Euclidean distance showed a clear separation between tumour and normal samples,
as expected. Within patient 3, where a large number of differentially expressed genes
were identified, and patient 15, where multiple privately enriched pathways were found,
TU1 and TU2 samples are more distant in comparison to the other patients which cluster
according to their sequencing method (Supplementary Figure S1 and Additional File S2).
 
Figure 2. Genetic and transcriptomic diversity in 16 patients. (A) Number of shared (orange) and private (yellow, blue)
mutations in the WES data set. A shared alteration was detected in both samples of a patient, whereas a private alteration
was only found in one of the two samples. The two biopsies of the same tumour are labelled “TU1” and “TU2”. (B) Number
of differentially expressed genes in the RNA-seq data set. (C) The most overrepresented Reactome pathways among the
differentially expressed genes. The colour indicates the alteration status.
2.2. In-Depth Sequencing of 826 Selected Genes in 89 ccRCC Patients
In the second phase, the cohort was extended to 89 ccRCC patients. From each patient,
two spatially separated biopsies of the primary tumour and a matched normal sample
were collected. This data set includes 14 patients from the WES data set (two samples were
removed due to an insufficient amount of material), and 75 additional patients. Utilising
our customised gene panel, we sequenced the 178 tumour and 89 normal samples at
high depth. The deep coverage enables the detection of low-frequency mutations, and
the larger cohort provides increased statistical power such that rare subclonal mutation
patterns can be detected. The sequenced reads contain unique molecular identifiers (UMIs),
which allows for the correction of potential sequencing errors. The coverage of the panel
sequencing (panel-seq) data set was on average 933x, and after UMI consensus building
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and read filtering, it was 93x. The number of SNVs as well as indels in the panel-seq data
set was on average 22 per patient (Figure 3, top panel). Pairwise comparison of the two
biopsies from the same tumour revealed that on average, 62% of the mutations in a patient
were private to one of the two samples with 87 of the 89 tumours (98%) containing at least
one private mutation. Among the most frequently mutated genes, only 10 were mutated in
more than 10% of the patients (only one in more than 50% of the patients), confirming the
long-tail phenomenon commonly seen in cancer cohorts [16].
The four most commonly mutated genes in ccRCC, VHL, PBRM1, SETD2 and BAP1 [17],
were also among the most frequently mutated genes in our data set (Figure 3, bottom panel).
Three mucin genes: MUC6 (42%), MUC16 (38%), and MUC3A (18%) were also frequently
mutated in our cohort. The mutation frequencies of VHL, SETD2, and BAP1 were 54%,
12%, and 13%, respectively and comparable to the frequencies found in the TCGA cohort.
Somewhat lower mutation frequencies were seen in TP53 (9%), mTOR (7%), and KDM5C
(7%), which were also reported in previous ccRCC studies [6,17,18]. Interestingly, in nine
patients, the VHL mutations resided in only one of the two tumour samples. The mutations
in VHL are known to occur early in tumour development [19,20], which is in line with our
observation that in 39 of 48 (81%) cases, the VHL mutations were shared between both
tumour biopsies of a patient. Private mutation was seen in all but two tumours; these
mutations were observed in one of the two tumour samples underlining the strong genetic
heterogeneity of ccRCC.
The number of mutations was unequally distributed between the two tumour biopsies
in each case with identified private mutations; this is pronounced in patients 16, 55 and 57.
Of the most frequently affected genes (Figure 3), three private mutations were found in
VHL, PBRML1, and SETD2 within TU2 of patient 16, whereas 14 private mutations were
identified in TU1. A private mutation was also found in each tumour biopsy affecting
the same gene: LAMA2. In patient 55, all seven private mutations in the most frequently
mutated genes occurred in TU2, while in patient 57, 13 private mutations were found in
TU2. Like patient 16, two private mutations in each tumour sample of patient 57 impacted
the same gene; however, in patient 57, that gene is LRP2. Only five patients had no
mutations in the most frequently affected genes (≥7%). In patient 88, the gene PBRM1
was hit by different mutations in the two tumour samples, demonstrating a pattern of
convergent phenotypic evolution where a gene is affected by multiple distinct mutations
across the clones in the tumour. One tumour sample, TU1, had a frameshift deletion and
a missense mutation, while the other tumour sample, TU2, had a missense mutation at
a different locus in PBRM1. Both subclonal missense mutations of PBRM1 are predicted
to be deleterious according to the SIFT annotation [21]. Among the most subclonally
affected genes in our data set were the mucins MUC6, MUC16, and MUC3A. A clonal
exclusivity test was applied to the cohort of 89 ccRCC patients on the gene level. This
test pinpoints the gene pairs that are mutated in the same patients but tend to be mutated
in different subclones, hence are mutually exclusive on the level of subclones. The most
striking gene pair was TP53 and MUC16, which was clonally exclusive in patients 5 and 81
(Supplementary Figure S2, Supplementary Table S1).
2.3. Pathway-Level Clonal Exclusivity in 16 Ccrcc Patients
To reconstruct the evolutionary history of the tumours and assign mutations to specific
clones, we used Cloe [23]. The WES data from paired tumour biopsies and matched normal
samples of 16 ccRCC patients enabled us to map the mutated genes to pathways and to
detect pathway pairs that are affected in several patients. The two most striking clonally
exclusive pathway pairs, i.e., pathways that are aberrated in different clones of the same
tumour in a mutually exclusive fashion, are “major pathway of rRNA processing in
the nucleolus and cytosol” (referred to as pathway 1), “O-glycosylation of TSR domain-
containing proteins” (pathway 2)}, and pathway 1, “defective B3GALTL causes Peters-plus
syndrome (PpS)” (pathway 3), which are clonally exclusive in both patients in which they
are affected (Figure 4A,B, Supplementary Table S3), namely, patients 8 and 14 (p < 10−5).
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Pathway 1 belongs to the category “metabolism of RNA”, while pathway 2 falls into the
class “metabolism of proteins”, and pathway 3 is a disease pathway related to diseases
of glycosylation [15]. Pathway 1 was also significantly enriched among the differentially
expressed genes in 13 of 16 patients of this cohort.
 
‒
Figure 3. Genetic diversity in the panel seq data of 89 ccRCC patients. Top: numbers of shared and private mutations in the
data set. Bottom: the heatmap highlights the mutations that were detected in the most frequently mutated genes. The four
most frequently altered genes in ccRCC are VHL, PBRM1, BAP1, and SETD2 [17] and are highlighted in bold. If a gene
was hit by multiple mutations that all have the same status (shared, private TU1, or private TU2), the following ordering is
applied to prioritise which colour is shown in the heatmap, starting with the highest priority: stop gained, start gained,
frameshift indel, inframe indel, missense, splice site, five prime UTR, three prime UTR, synonymous. That means, if a gene
has, e.g., a missense and a synonymous mutation, the missense mutation will be displayed in the heatmap. The variants
were annotated with SnpEff [22] (Supplementary Table S2). Mutations in non-coding regions are omitted from the heatmap.
Aside from inferring the mutation-to-clone assignment, the Cloe software also esti-
mates the fractions of the clones in each sample (Figure 4C). This is important in order to
interpret possible changes on the transcriptomic level in the bulk samples. Pathway 1 was
mapped to clones 1 and 2 in patient 8 (Figure 4B), which together have a clonal faction of
47.5% and 30.7% in samples TU1, and TU2, respectively (Figure 4C). Pathway enrichment
analysis shows that pathway 1 is also highly overrepresented in these two samples on
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the transcriptomic level (Figure 4D). Pathways 2 and 3 were assigned to clone 3 which
is, with 16.6%, the most abundant in sample TU2 of patient 8 (Figure 4C). Pathway 2 is
also enriched among the differentially expressed genes in this sample, but pathway 3 is
not suggesting that the underlying mutations seem to alter the expression of pathway 2
(Figure 4D). Pertaining to patient 14, no enrichment of pathway 1 could be found in either
sample (Figure 4D). Pathway 1 was assigned to clone 2, which was estimated to have a
clonal fraction of only 8.6% and 0.2% in samples TU1 and TU2, respectively (Figure 4C),
which may explain why there was no signal detectable in the bulk transcriptome samples
for this pathway. Pathways 2 and 3, however, were assigned to clone 3 (Figure 4B), which
has an estimated clonal fraction of 0.5% and 12.8% in samples TU1 and TU2, respectively.
In both bulk RNA samples, pathways 2 and 3 were enriched in the second tumour sample.
 
Figure 4. The two most striking clonally exclusive pathway pairs from the clonal exclusivity test when performed on the
pathway level of the WES data set from 16 ccRCC patients. The pathway pairs are affected in patients 8 and 14 and in each
patient, a different subset of genes is mutated. Hence, this clonal exclusivity pattern is only detectable on the pathway level.
(A) The table displays the genes that are mutated in these pathways. (B) The heatmaps illustrate in which clones the genes
in these pathways are mutated. (C) The proportion of cells from the clones in each of the two samples from the two patients.
The label “N” represents the fraction of normal cells in the biopsy. (D) The data set also includes RNA-seq data from each
sample. Among the differentially expressed genes in each sample, the pathways are significantly overrepresented in some
of the samples.
3. Discussion
We analysed intra-tumour heterogeneity using two ccRCC patient cohorts. In the first
phase, the investigation of the WES and RNA-seq data of 16 ccRCC patients revealed that
intra-tumour heterogeneity is very pronounced on the genetic level, with an average of
40% of mutations found to be private. We also found that 31% of differentially expressed
genes were detected in only one of the two patient tumour biopsies. In the second phase,
the extended cohort of 178 tumour biopsies and the deep sequencing coverage enabled us
to detect not only rare subclonal mutations, especially in TP53 and mucin coding genes
MUC6, MUC16, and MUC3A, but also early genomic alterations such as PBRM1 and VHL
with enough statistical power.
Intra-tumour heterogeneity has been reported previously by Gerlinger et al. in 2012.
Following the extraction of 30 samples from four tumours, those authors observed up
to 69% of somatic mutations not to be present within all samples [2]. In the same year,
the analysis of 25 single cells from one ccRCC patient revealed the large extent of genetic
heterogeneity between different tumour cells [24]. These studies of intra-tumour hetero-
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geneity in ccRCC reported patterns of convergent phenotypic evolution in several genes
including VHL, BAP1, SETD2, PBRM1, PIK3CA, PTEN, and KDM5C [2,4], which were also
among the most frequently mutated genes in our cohort. ccRCC development is largely
driven by the loss of one gene, VHL. Tumourigenesis typically starts with a large deletion
on chromosome 3p, followed by mutational VHL inactivation. In addition to VHL, the 3p
deletion also removes one copy of PBRM1, BAP1, and SETD2. Since VHL inactivation alone
is insufficient [25], mutations in PBRM1 and BAP1 are necessary for ccRCC development.
Importantly, these mutations tend to be mutually exclusive [19]. Interestingly, we have seen
VHL mutations in only one of the two tumour samples in nine out of eighty-nine patients.
This implies that these alterations would have been missed if the other tumour piece was
analysed alone, with the consequence that these tumours would have been considered as
VHL wild-type ccRCC. While VHL mutations are considered truncal, we hypothesize that
in these nine samples, the mutated allele was lost in the respective subclone [26–28].
In addition, some of the genes were affected by multiple distinct mutations across
the clones in the tumour. This is comparable to some of our previous findings in the VHL
gene [3]. PBRM1 mutations occur in 19% of the patients in our cohort, which is less than
the frequency reported from TCGA [17,18]. We found a pattern of convergent phenotypic
evolution in PBRM1: the gene was hit by two different deleterious missense mutations in
each of the two biopsies of one patient.
We identified frequent subclonal mutations in MUC6, MUC16, and MUC3A, indicating
that alterations of these mucin genes may also be critical in ccRCC development. In the
TCGA data set, the mucins MUC4, and MUC16 were also among the seven most frequently
mutated genes [17], but our mutation frequencies of MUC6, MUC16, and MUC3A are
42%, 38%, and 18%, higher than those reported in TCGA [17]. In previous ccRCC studies,
MUC16 was reported to be among the most recurrently mutated genes [18,29]. Our analysis
of the mutation distribution within the MUC16 (also termed CA125) amino acid sequence
revealed that non-silent mutations seem to be clustering at the end of the sequence in the
SEA domains (Supplementary Figure S3) whose precise function is not known. These
extracellular SEA domains can be extensively O-glycosylated and it was suggested that they
can bind nucleic acids or sugars, or be released through cleavage [30]. In this context, it is of
note that several RCC studies reported an association between increased levels of MUC16,
poor prognosis and advanced tumour stage, suggesting the potential use of MUC16 as
a serum biomarker in RCC [31–33]. Although MUC16 had one of the highest mutation
frequencies, our immunohistochemistry analysis showed no expression of MUC16 in the
ccRCC samples (data not shown, see methods for IHC protocol). How mutations in SEA
domains affect MUC16′s function and contribute to its release in the serum in ccRCC
patients remains to be evaluated. It was shown that in lung cancer, MUC16 mutations can
lead to its oncogenic upregulation [34] and the overexpression of MUC16 is associated
with increased tumour cell growth, cancer cell migration, and resistance to cytotoxic
drugs [35]. Recent studies also discovered frequent non-silent MUC16 mutations in breast
cancer [36,37], another cancer type in which MUC16 was observed to be overexpressed [38].
Furthermore, MUC16 mutations have been implicated as cancer-driving in a pan-cancer
analysis that assessed the functional impact of mutations on differential gene expression
profiles [39].
The majority of mucin gene mutations found in our cohort have a low variant allele
frequency (VAF). Specifically, more than 75% of the mutations in MUC6, MUC16, and
MUC3A have a VAF below 10%, and almost half below 5%. Given the mostly low VAFs of
mutated mucin genes in our study, the analysis of the effect of mutations on mucin protein
expression and its prognostic value would be very challenging. MUC6 and MUC16 protein
expression is hardly detectable in ccRCC and MUC3A show weak to moderate expression
in all ccRCC analysed (Human Protein Atlas and own data (MUC16), not shown). Despite
the difficult interpretation of varying positivity of MUC3A, an increased expression of this
mucin was correlated with poor prognosis in localised ccRCC [40].
Cancers 2021, 13, 2163 9 of 18
Besides MUC6, MUC16 and MUC3A, additional mucins may play an important role in
ccRCC, as their expression level was shown to be predictive of clinical outcome. Decreased
expression of Mucin 4 and Mucin 18 predicted poor prognosis [41,42] whereas high Mucin
7, Mucin 5A, and Mucin 13 expression was found to be associated with worse patient
outcome [43–45].
TP53, a well-known tumour suppressor, was found to be mutated in less than 10% of
ccRCC [17,18,46,47], which is confirmed in the cohort analysed here (9%). TP53 mutations
were associated with the reduced survival of renal cancer patients [48,49]. Of note, a previ-
ous study of the intra-tumour diversity in ten ccRCC cases revealed that mutation in TP53
were one of the most extreme examples of gene mutations being detected more often when
sequencing multiple biopsies per tumour instead of a single one [4]. We confirmed this
finding as four of eight mutations were detected in only one of the two tumour samples.
This observation suggests that TP53 mutations may be a crucial subclonal event in ccRCC
and explains the low prevalence of TP53 mutations in earlier studies. Motzer et al. have
evaluated somatic alterations across different histological subtypes and reported a lower
prevalence of PBRM1 mutations in ccRCC with sarcomatoid differentiation, whereas TP53
mutations had an increased prevalence in non-ccRCC with sarcomatoid differentiation.
Sarcomatoid RCC exhibited a highly proliferative phenotype with high immune presence
and PD-L1 expression, explaining increased sensitivity to therapeutic intervention with
atezolizumab+bevacizumab versus sunitinib [50,51]. Similar to non-ccRCC with sarcoma-
toid differentiation, subclonal TP53 mutations could also be a first molecular step into the
development of an aggressive phenotype of ccRCC leading to sarcomatoid differentiation.
Motzer et al. have recently identified seven ccRCC subtypes with specific angiogenesis,
immune, metabolic, stromal, and cell-cycle profiles showing differential clinical outcomes
to VEGF blockade alone or in combination with anti-PD-L1 [14]. These molecular clades
have a differential prevalence of TP53, PBRM1, KDM5C, and CDKN2A/2B alterations.
Our observation of subclonal TP53 mutations suggests that primarily tissue samples with
sarcomatoid differentiation may display high levels of intra-tumour heterogeneity.
A total of 87 tumours (98%) had private mutations and were detectable in only one of
two tumour samples. Given the relatively large tumour volumes of ccRCC, with pT1 and
pT2 tumours having diameters of up to 7 and 11 cm, respectively, spatial heterogeneity
represents a tremendous challenge to individual therapy. Underrating the mutational
burden due to spatial heterogeneity of gene alterations is thus a common problem in cancer
research as well as in molecular tumour diagnostics. Single cell analysis and appropriate
bioinformatics tools may help to overcome this bottleneck, particularly if only single little
tumour biopsies are available.
Within a subset of patients, we see a large difference in mutational counts between the
two biopsies. These differences could arise due to differences in tumour purity or perhaps
aberrations affecting genes needed for DNA damage repair, resulting in an accumulation
of mutations [52]. We controlled for tumour purity with our requirement of at least 70%
tumour cells and so explored the potential aberrations in genes involved in DNA repair
obtained from MutSigDB [53]. Missense mutations were found in both ERCC1 and POLR2A
in TU1 of patient 16. ERCC1, together with XPF, forms a nuclease essential for nucleotide
excision repair with ERCC1 required for DNA binding [54,55]. POLR2A encodes the largest
subunit of RNA polymerase II (RNAPII). RNAPII initiates the recruitment of transcription-
coupled nucleotide excision repair factors such as CSB when stalling at DNA lesions
blocking translation [56]. Dysfunction in just one of these proteins may lead to an increase
in the number of mutations, as seen in TU1 of patient 16. In TU2 of patient 55, we identified
downstream intron variants of XPC that produce a protein of the same name functioning to
recognise DNA damage during the global genome–nucleotide excision repair pathway [57].
Although these XPC variants have not been classed as altering XPC function, given the
large difference seen between TU1 and TU2 in patient 55, these variants may be a cause of
the accumulation of mutations observed in the second biopsy.
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In an attempt to identify co-existing clones with affected pathways related to the
metabolism of proteins and RNA, we applied a clonal exclusivity test to 16 ccRCC patients
on the pathway level. This test allows the identification of pathways that are perturbed
in different clones of the same tumour in a mutually exclusive fashion. These pathway
alterations occurred in clones that evolved in parallel along different branches of the
tumour phylogeny. The two most striking pathway pairs include “major pathway of
rRNA processing in the nucleolus and cytosol” (pathway 1), which is clonally exclusive
with “O-glycosylation of TSR domain-containing proteins” (pathway 2) and “defective
B3GALTL causes Peters-plus syndrome (PpS)” (pathway 3) (Figure 4A). The pathway
pairs {1, 2} and {1, 3} are affected in the two patients through a different subset of genes
(Figure 4A), namely WDR18 and THSD4 in patient 8, and DDX49 and ADAMTS14 in
patient 14. ADAMTS14 belongs to the ADAMTS protein family, which are secreted zinc
metalloproteases that play a role in the extracellular matrix related to angiogenesis and
cancer [58]. THSD4 is also referred to as ADAMTS-like protein 6 and is also secreted to the
extracellular matrix [59]. Both ADAMTS14 and THSD4 contain the thrombospondin type
1 repeat (TSR) domain [60]. The proteins with TSR domains can undergo O-fucosylation,
a protein modification that plays a role in angiogenesis and Notch signalling [60–62]. To
conclude, the pathways detected as clonally exclusive (pathways 1, 2, and 3) are also
enriched among the differentially expressed genes in some of the samples. Pathways
2 and 3 are functionally deregulated in only one of the two biopsies, showing that this
deregulation is subclonal. The deregulation may arise due to the mutations in THSD4 and
ADAMTS14, which are members of these pathways. Whilst being of interest, the exclusivity
pattern was observed in two patients, and therefore validation of these findings in a larger
cohort would be beneficial.
4. Materials and Methods
4.1. Experimental Design
The analysis of intra-tumour heterogeneity and subclonal mutation patterns was
comprised of two phases (Figure 1). In an initial discovery phase, whole-exome and
transcriptome sequencing data from paired tumour biopsies from 16 ccRCC patients plus
one matched normal sample per patient were analysed to obtain an overview of the
diversity in these samples. In this first exploratory step, the detected mutations informed
the design of our gene panel for the second phase. Furthermore, frequently mutated ccRCC
genes from the publicly available data sets provided by the Cancer Genome Atlas Research
Network (TCGA) [17] were considered for the selection of genes in the panel. During
the second phase, a total of 826 selected genes were then targeted at deep coverage in an
extended cohort of 89 patients for a detailed analysis of tumour heterogeneity.
4.2. Patient Material
Two cohorts of 16 and 89 ccRCC patients with no prior treatment were chosen for
the sequence analyses. The tumours of these ccRCC patients were classified according to
the 2016 WHO classification [63] and reviewed by H.M. From each patient, two tumour
samples and one matched normal tissue were selected. From each frozen and FFPE
tissue block, haematoxylin and eosin stained sections were prepared and reviewed by a
pathologist (H.M.) to ensure tissue integrity. Only tumours with at least 70% tumour cells
were included in our cohort. For whole exome and RNA sequencing of 48 (16 × 3) tissue
samples, 5–10 frozen sections (10 µm) were used for DNA and RNA extraction. For in depth
sequencing, 3 punches (0.6 mm diameter) were taken from 267 (89 × 3) formalin-fixed,
paraffin-embedded tissue blocks. All tissue samples were anonymised.
4.3. Whole Exome Sequencing
The first data set encompasses two spatially separated primary tumour biopsies and
one matched normal sample from each of the sixteen clear cell renal cell carcinoma (ccRCC)
patients. The whole exome was sequenced using the Illumina HiSeq 2000 system to obtain
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101-bp paired-end reads. The computational pipeline to analyse the data was a customised
version of the NGS-pipe framework [64] that included the following steps: adapter clip-
ping and trimming of low-quality bases with Trimmomatic [65], alignment of the reads
to the human reference genome version hg19 using bwa [66], and read processing with
SAMtools [67], Picard tools [68], and bam-readcount. Reads were realigned locally around
indels, and base qualities were recalibrated with the Genome Analysis Toolkit (GATK) [69].
Single-nucleotide variants (SNVs) were called using the rank-combination [70] of deep-
SNV [3], JointSNVMix2 [71], MuTect [72], SiNVICT [73], Strelka [74], and VarScan2 [75].
The rank-combination is a method that combines the results of different variant callers by
integrating the ranked lists of variants to generate a combined ranking [70]. P-values of
deepSNV were corrected for multiple testing with the R package IHW [76]. Indels were
called using SiNVICT [73], Strelka [74], VarDict [77], and VarScan2 [75], and combining
them with the rank-combination [70]. For copy number variant detection, the tool Se-
quenza [78] was employed. Mutations in copy number neutral regions were selected as
input for Cloe [23] in order to reconstruct the evolutionary history of a tumour and to
assign the mutations to different clones. In order to account for the uncertainty in the
phylogenetic tree inference, Cloe was run 20 times with different seeds.
4.4. Transcriptomic Data Generation and Analysis
Paired-end and single-end RNA-sequencing was performed on the Illumina HiSeq
2000 system to generate 101-bp paired-end reads, and 51-bp single-end reads for the
48 samples from the initial 16 patients. For the computational analysis, the NGS-pipe
framework was adapted [64]. Reads were clipped and trimmed using Trimmomatic [65],
and alignment was performed with STAR [79]. Read counts for the genes were obtained
with the program featureCounts [80]. Differential gene expression analysis was carried out
using DESeq2 [81], comparing each tumour sample to its paired normal sample using both
single and paired-end data (i.e., a 2 vs. 2 design). Genes with a q-value less than 0.01 were
considered differentially expressed. The R package WebGestaltR [82] was applied to per-
form enrichment analysis using all differentially expressed genes (up- and downregulated)
together. As a background gene list for the enrichment analysis, only expressed genes were
included. More precisely, in each comparison of a patient’s tumour samples to the matched
normal samples, the expressed genes were included in the background gene list if they had
at least a count of 10 fragments across the tumour and normal samples.
4.5. Panel Sequencing
The second data set is a panel sequencing data set. It comprises an extended cohort of
patients from which a selected set of genes were sequenced at higher depth. The selection of
826 genes was informed by the mutated genes detected in the WES data set, as well as from
the frequently mutated ccRCC genes in TCGA [17] (see Additional Files S3 and S4 for the
826 gene list and bed file). We generated panel-seq data from 89 ccRCC patients, including
two spatially separated primary tumour biopsies, and a matched normal sample per patient.
This data set comprises 14 of the patients from the WES data set, and 75 additional patients.
The data were sequenced using the Illumina HiSeq 2500 system. The sequenced reads
contain unique molecular identifiers (UMIs), and this allows for the correction of potential
sequencing errors. Reads with identical UMIs, which are mapped to the same genomic
position, come from the same DNA molecule, and therefore, the consensus sequence can
be built, and the variants can be called with higher confidence.
The pipeline for analysing the sequencing data was again a customised version of
the NGS-pipe framework [64] including the following steps: raw reads were clipped and
trimmed using the tool SeqPurge [83]. Reads were aligned to the human reference genome
version hg19 with the aligner bwa [66]. Reads were further processed using SAMtools [67],
Picard tools [68] and bam-readcount. Local realignment around indels was carried out with
GATK [69]. We used the software UMI-tools [84] to group reads with identical UMI and
identical mapping position together, and an in-house tool to build the consensus sequence
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and thereby correct sequencing errors. Our in-house tool takes the grouped reads with
identical UMIs and identical mapping positions and attempts to generate the consensus
sequence from these grouped reads. If the reads contain contradicting bases at a nucleotide
position, it is masked with the base “N”. The SNV and indel calling was similar as for the
WES data set. Some of our samples are from formalin-fixed paraffin-embedded (FFPE)
material. FFPE samples are known to harbour artificial C > T and G > A alterations [85,86].
They occur mostly at lower frequencies in the range between 1–10% variant allele frequency
(VAF), since the DNA damage occurs at different genomic positions in different cells [85,87].
To remove potential FFPE artefacts, we filtered out C > T and G > A mutations that had a
VAF < 10%. The tool Cloe [23] used for the tree inference requires as input mutations in
copy number-neutral regions. In order to filter out mutations that are in potential copy
number variant regions, mutations that are within 4000 bps of an imbalanced heterozygous
germline SNP were filtered out. An imbalanced heterozygous germline SNP is a SNP that
has a VAF between 40–60% in the normal sample, but in the tumour sample the VAF is out
of these bounds, indicating a potential copy number change. Finally, in order to perform
quality control we used Qualimap [88] and FastQC [89] in the WES and panel sequencing
data sets.
4.6. Testing for Pathway-Level Clonal Exclusivity
The mutations detected in the WES data set were assigned to clones with Cloe [23],
mapped to genes, and subsequently, the genes were mapped to pathways using the Reac-
tome pathway database [15]. This procedure resulted in a total of 877 affected pathways.
For functional annotation of the variants, SnpSift [90] and SnpEff [22], as well as the
data bases COSMIC [47] version 80, and dbSNP [91] version 138 were used. In order
to identify pathways that are altered in a clonally exclusive fashion, we employed the
statistical test implemented in GeneAccord [92]. We only kept genes with a potential
impact for this analysis. While mutations such as synonymous or intronic variants are
informative for the tree inference, they were not of interest for the clonal exclusivity test.
Non-silent mutations are more likely to change the phenotype of the clones and therefore
these mutations are potential candidates for inducing clonal interactions. For the estimation
of background rates of clonal exclusivity and co-occurrence, it is therefore important to
focus on non-silent mutations in order to have accurate estimates of their clonally exclusive
background distribution. To filter out silent mutations, we used the annotation program
SnpEff, which classifies variants into four categories based on the potential impact of
the mutation [22]. These are, in descending order of importance, the categories “HIGH”,
“MODERATE”, “LOW”, and “MODIFIER”. Examples of the category “HIGH” would be
frameshift indels. Missense mutations and inframe indels are classified as “MODERATE”.
The category “LOW” includes synonymous and splice region mutations. Variants that
are annotated as “upstream”, “intronic”, or “UTR region” fall into the class “MODIFIER”.
For the GeneAccord-based clonal exclusivity analysis, we kept mutations that are in the
category “HIGH”, “MODERATE”, and from the class “LOW” we kept all variants with the
exception of: synonymous variants, or mutations that are annotated as the case where a
start codon mutates into another start codon, or analogous for stop codon. To sum up, we
kept variants such as missense, frameshift or inframe indel or variants in splice regions,
but filtered out variants that are synonymous, intronic or in the UTR regions.
4.7. Statistical Analysis
For the data analysis in R [93] as well as for visualising results, several R packages
were used including biomaRt [94,95], caTools [96], dplyr [97], ggplot2 [98], ggpubr [99],
gtools [100], maxLik [101], tibble [102], magrittr [103], reshape2 [104], RColorBrewer [105],
ComplexHeatmap [106], and survival [107].
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4.8. Immunohistochemistry
TMA sections (2.5 µm) on glass slides were subjected to immunohistochemical anal-
ysis stained using Ultra Discovery (Ventana, Roche Diagnostics, Rotkreuz, Switzerland).
MUC16/CA125 was immunostained using monoclonal mouse anti-MUC16 antibody (clone
X75, cat. no. M1-90039; Invitrogen, diluted 1:1000 in Bond medium). MUC16 was made vis-
ible using IHC Refine kits (Ventana). Normal and tumour tissue (cut off: >5% tumour cells)
were considered MUC16-positive if tumour cells showed unequivocal weak, moderate or
strong cytoplasmic and membranous expression.
5. Conclusions
In summary, the systematic analysis of the clone constellations as performed here in
large patient cohorts will contribute towards a better understanding of the evolutionary
forces beyond mutation and selection that drive tumour evolution and will help to improve
treatment strategies available for those with ccRCC.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/cancers13092163/s1, Figure S1: Euclidean distances between samples of each patient, Figure S2:
Number of mutated genes per patient used as input for GeneAccord & average rates of clonal
exclusivity per patient, Figure S3: MUC16 mutations, Table S1: The 16 gene pairs with a positive
parameter delta of the clonal exclusivity test applied to the 89 ccRCC, Table S2: The variant categories
from Figure 3 and the corresponding annotations from SnpEff, Table S3: The ten most striking
pathway pairs with a positive parameter delta of the clonal exclusivity test applied to the 16 ccRCC
on the pathway level, Additional File 2: Euclidean distance matrices (.txt), Additional File 3: 826 gene
panel, Addi-tional File 4: BED file corresponding to gene panel.
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